TLDR:
- Adaptilens secures $17.5M Series A financing led by Perceptive Xontogeny Venture Funds
- Company aims to revolutionize cataract surgery standard of care with Accommodating Intraocular Lens (A-IOL)
Adaptilens, Inc., a pre-clinical company based in Boston, announced the closing of a Series A financing round of $17.5 million. The funding, led by Perceptive Xontogeny Venture Funds, aims to support the development of the company’s innovative Accommodating Intraocular Lens (A-IOL) through first-in-human trials. The A-IOL, described as the first and only biomimetic intraocular lens, seeks to transform the standard of care for cataract surgery.
The National Eye Institute’s projections indicate that the number of Americans with cataracts is expected to double by 2050, making cataract surgery a critical healthcare need. Adaptilens’s A-IOL, a novel flexible lens that mimics the eye’s natural focusing mechanism, aims to restore clear near, intermediate, and distance vision without the need for eyeglasses or contact lenses. The company’s mission is to revolutionize cataract surgery by providing a biomimetic option that restores youthful vision.
Perceptive Xontogeny Venture Funds expressed excitement about Adaptilens’s innovative technology and the potential impact of the A-IOL design on the millions of people in need of cataract surgery. The company’s unwavering dedication to developing a best-in-class A-IOL has garnered support from investors and positioned them for growth from pre-clinical to clinical stages.
Overall, Adaptilens’s Series A financing represents a significant step towards realizing their vision of transforming the standard of care for cataract surgery and improving the quality of life for individuals undergoing the procedure.
